Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to Earnings
- Prudential Bancorp of Penn. (PBIP) Swings to Q4 Profit
- Pharmasset (VRUS) Reports Inline Q4 Loss of $0.53
- Sterling Banks (STBK) Swings to Q3 Loss
- Highlights From DE's Q4 Conference Call: Production Will Pick Up in 2010, But Overall Conditions to Remain Fairly Restrained
- Highlights From TIF's Q3 Conference Call: Sales Declines, But Less-Than-Expected; Raises FY Outlook
Endo Pharmaceuticals (NASDAQ: ENDP) reports Q3 EPS of $0.63, versus the analyst estimate of $0.64. Revenue for the quarter was $361.03 million, which compares to the estimate of $365.33 million.
Raises FY09 Guidance to $1.44 - $1.465 billion., and FY09 adjusted EPS expected to be $2.67 - $2.73.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.27Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
